

# Farrokh Dehdashti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5276615/publications.pdf>

Version: 2024-02-01

139  
papers

11,141  
citations

30551

56  
h-index

33145

104  
g-index

142  
all docs

142  
docs citations

142  
times ranked

9735  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Projection-Domain Low-Count Quantitative SPECT Method for $^{67}\text{Ga}$ -Particle-Emitting Radiopharmaceutical Therapy. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2023, 7, 62-74.	2.7	4
2	Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 550-562.	3.3	48
3	$^{18}\text{F}$ -FDG PET in Myocardial Viability Assessment: A Practical and Time-Efficient Protocol. <i>Journal of Nuclear Medicine</i> , 2022, 63, 602-608.	2.8	2
4	Coronary circulatory function with increasing obesity: A complex Uâ€turn. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13755.	1.7	10
5	$^{18}\text{F}$ -FDG PET/CT Staging of Head and Neck Cancer: Interobserver Agreement and Accuracyâ€Results from Multicenter ACRIN 6685 Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1887-1890.	2.8	1
6	An Exploratory Study of Neoadjuvant Cetuximab Followed by Cetuximab and Chemoradiotherapy in Women With Newly Diagnosed Locally Advanced Cervical Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 286-293.	0.6	0
7	Pilot Study: PARP1 Imaging in Advanced Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2022, 24, 853-861.	1.3	3
8	Durable remission after rechallenge with ipilimumab and nivolumab in metastatic Merkel cell carcinoma refractory to avelumab: Any role for sequential immunotherapy?. <i>Journal of Dermatology</i> , 2021, 48, e80-e81.	0.6	10
9	CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. <i>ACS Nano</i> , 2021, 15, 1186-1198.	7.3	32
10	Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy. <i>Nature Communications</i> , 2021, 12, 733.	5.8	33
11	Standardized Uptake Value for $^{18}\text{F}$ -Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4245-4255.	3.2	15
12	Detection of additional primary neoplasms on $^{18}\text{F}$ -Fluciclovine PET/CT in patients with primary prostate cancer. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262647.	2.8	3
13	PET Imaging for Gynecologic Malignancies. <i>Radiologic Clinics of North America</i> , 2021, 59, 813-833.	0.9	6
14	Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes. <i>Theranostics</i> , 2021, 11, 9721-9737.	4.6	12
15	Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma. <i>Rare Tumors</i> , 2021, 13, 203636132110524.	0.3	1
16	Radiologic Assessment of Groin Lymph Nodes in Pelvic Malignancies. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 947-953.	1.2	4
17	Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa. <i>Case Reports in Oncology</i> , 2020, 13, 911-915.	0.3	14
18	FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. <i>Gynecologic Oncology</i> , 2020, 157, 639-643.	0.6	57

#	ARTICLE	IF	CITATIONS
19	Repeatability of Quantitative Brown Adipose Tissue Imaging Metrics on Positron Emission Tomography with <sup>18</sup> F-Fluorodeoxyglucose in Humans. <i>Cell Metabolism</i> , 2019, 30, 212-224.e4.	7.2	21
20	Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1088-1097.	0.4	57
21	Molecular Imaging for Radiotherapy Planning and Response Assessment for Cervical Cancer. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 493-500.	2.5	15
22	A Role of PET Agents Beyond FDG in Gynecology. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 501-511.	2.5	6
23	Assessment of Copper Nanoclusters for Accurate in Vivo Tumor Imaging and Potential for Translation. <i>ACS Applied Materials &amp; Interfaces</i> , 2019, 11, 19669-19678.	4.0	37
24	Measurement Repeatability of <sup>18</sup> F-FDG PET/CT Versus <sup>18</sup> F-FDG PET/MRI in Solid Tumors of the Pelvis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1080-1086.	2.8	23
25	Impact of tumor histology on detection of pelvic and para-aortic nodal metastasis with <sup>18</sup> F-fluorodeoxyglucose-positron emission tomography in stage IB cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1351-1354.	1.2	8
26	Evaluation of [ <sup>89</sup> Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 523-530.	1.1	59
27	Preclinical Development of CD38-Targeted [ <sup>89</sup> Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 216-222.	2.8	50
28	Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer. <i>British Journal of Cancer</i> , 2018, 118, 72-78.	2.9	46
29	Percutaneous Minimally Invasive Thermal Ablation of Musculoskeletal Lesions. <i>PET Clinics</i> , 2018, 13, 579-585.	1.5	4
30	Spatial relationship of 2-deoxy-2-[ <sup>18</sup> F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer. <i>EJNMMI Research</i> , 2018, 8, 52.	1.1	11
31	Pretreatment metabolic tumor volume as a prognostic factor in HPV-associated oropharyngeal cancer in the context of AJCC 8th edition staging. <i>Head and Neck</i> , 2018, 40, 2280-2287.	0.9	14
32	Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. <i>Lancet Oncology</i> , 2018, 19, 1082-1093.	5.1	21
33	Extensive Metastatic Sarcomatoid Renal Cell Carcinoma Evaluated by <sup>18</sup> F-FDG PET/CT: a Case Report and Review of Literature. <i>Journal of Kidney Cancer and VHL</i> , 2018, 5, 1-6.	0.2	7
34	Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial. <i>Radiology</i> , 2017, 283, 450-459.	3.6	51
35	Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial. <i>Clinical Cancer Research</i> , 2017, 23, 2186-2194.	3.2	37
36	Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva. <i>Radiotherapy and Oncology</i> , 2017, 122, 445-451.	0.3	12

#	ARTICLE	IF	CITATIONS
37	Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2017, 11, 338-345.	1.3	9
38	First-in-Man Evaluation of <sup>124</sup> I-PGN650: A PET Tracer for Detecting Phosphatidylserine as a Biomarker of the Solid Tumor Microenvironment. <i>Molecular Imaging</i> , 2017, 16, 153601211773334.	0.7	12
39	Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent. <i>Oncotarget</i> , 2017, 8, 104303-104314.	0.8	12
40	Clinical application of PET/MRI in oncology. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 265-276.	1.9	45
41	Indeterminate Findings on Oncologic PET/CT: What Difference Does PET/MRI Make?. <i>Nuclear Medicine and Molecular Imaging</i> , 2016, 50, 292-299.	0.6	9
42	Gold Nanoclusters Doped with <sup>64</sup> Cu for CXCR4 Positron Emission Tomography Imaging of Breast Cancer and Metastasis. <i>ACS Nano</i> , 2016, 10, 5959-5970.	7.3	71
43	Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: Another step forward. <i>Blood Reviews</i> , 2016, 30, 389-399.	2.8	9
44	Phase 1 Evaluation of [ <sup>64</sup> Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors. <i>Molecular Imaging and Biology</i> , 2016, 18, 446-453.	1.3	40
45	Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial. <i>Gynecologic Oncology</i> , 2016, 142, 413-419.	0.6	65
46	The Emerging Role of PET/MR Imaging in Gynecologic Cancers. <i>PET Clinics</i> , 2016, 11, 425-440.	1.5	18
47	Clinical application of PET/MRI in oncology. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, spcone-spcone.	1.9	0
48	[ <sup>89</sup> Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 952-959.	1.3	103
49	Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 75S-80S.	2.8	43
50	Imaging of Plasma Cell Dyscrasias with FDG-PET/MRI: A Single-Center Experience. <i>Blood</i> , 2016, 128, 5611-5611.	0.6	1
51	PET/MRI Evaluation of Gynecologic Malignancies and Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 293-303.	2.5	32
52	[ <sup>18</sup> F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. <i>Molecular Therapy</i> , 2015, 23, 1110-1122.	3.7	18
53	Evaluation of Hypoxia With Copper-Labeled Diacetyl-bis(N-Methylthiosemicarbazone). <i>Seminars in Nuclear Medicine</i> , 2015, 45, 177-185.	2.5	34
54	PET/MRI for the body imager: abdominal and pelvic oncologic applications. <i>Abdominal Imaging</i> , 2015, 40, 1387-1404.	2.0	23

#	ARTICLE	IF	CITATIONS
55	Longitudinal Noninvasive Imaging of Progesterone Receptor as a Predictive Biomarker of Tumor Responsiveness to Estrogen Deprivation Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 1063-1070.	3.2	31
56	Evaluation of Gynecologic Cancer with MR Imaging, <sup>18</sup> F-FDG PET/CT, and PET/MR Imaging. <i>Journal of Nuclear Medicine</i> , 2015, 56, 436-443.	2.8	90
57	Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in high risk endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5524-5524.	0.8	1
58	Utility of PET-CT vs CT alone to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5585-5585.	0.8	0
59	Suicide genes: monitoring cells in patients with a safety switch. <i>Frontiers in Pharmacology</i> , 2014, 5, 241.	1.6	10
60	A prospective trial comparing FDG $\alpha$ -PET / CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck. <i>Cancer Medicine</i> , 2014, 3, 1493-1501.	1.3	13
61	Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: a pilot study. <i>NMR in Biomedicine</i> , 2014, 27, 681-691.	1.6	26
62	A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 553-553.	0.8	0
63	Prognostic value of 18F-FDG PET metabolic parameters in oropharyngeal squamous cell carcinoma. <i>Journal of Radiation Oncology</i> , 2013, 2, 27-34.	0.7	30
64	Response to the Letter to the Editor Regarding the Manuscript Entitled $\alpha$ Positron Emission Tomography with [18F]-3 $\alpha$ -Deoxy-3 $\alpha$ -Fluorothymidine (FLT) as a Predictor of Outcome in Patients with Locally Advanced Resectable Rectal Cancer: A Pilot Study $\alpha$ . <i>Molecular Imaging and Biology</i> , 2013, 15, 786-787.	1.3	0
65	Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. <i>Gynecologic Oncology</i> , 2013, 130, 64-68.	0.6	73
66	A phase 2 trial of induction $\alpha$ paclitaxel and cetuximab given with cisplatin and 5 $\alpha$ -fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2013, 119, 766-773.	2.0	31
67	Positron Emission Tomography with [18F]-3 $\alpha$ -Deoxy-3 $\alpha$ -fluorothymidine (FLT) as a Predictor of Outcome in Patients with Locally Advanced Resectable Rectal Cancer: a Pilot Study. <i>Molecular Imaging and Biology</i> , 2013, 15, 106-113.	1.3	22
68	Tumor volume and subvolume concordance between FDG $\alpha$ -PET/CT and diffusion $\alpha$ -weighted MRI for squamous cell carcinoma of the cervix. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 431-434.	1.9	44
69	Novel Methods and Tracers for Breast Cancer Imaging. <i>Seminars in Nuclear Medicine</i> , 2013, 43, 324-329.	2.5	52
70	11C-Acetate PET/CT Before Radical Prostatectomy: Nodal Staging and Treatment Failure Prediction. <i>Journal of Nuclear Medicine</i> , 2013, 54, 699-706.	2.8	81
71	Assessment of Cellular Proliferation in Tumors by PET Using <sup>18</sup> F-ISO-1. <i>Journal of Nuclear Medicine</i> , 2013, 54, 350-357.	2.8	76
72	Assessment of Progesterone Receptors in Breast Carcinoma by PET with 21- <sup>18</sup> F-Fluoro-16 $\beta$ ,17 $\beta$ -[( <i>R</i> )-(1 $\alpha$ - $\beta$ -furylmethylidene)Dioxy]-19-Norpregn-4-Ene-3,20-Dione. <i>Journal of Nuclear Medicine</i> , 2012, 53, 363-370.	2.8	71

#	ARTICLE	IF	CITATIONS
73	Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer. <i>Radiotherapy and Oncology</i> , 2012, 102, 239-245.	0.3	183
74	FDG-PET-based prognostic nomograms for locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2012, 127, 136-140.	0.6	96
75	The role of positron emission tomography for non-small cell lung cancer. <i>Practical Radiation Oncology</i> , 2011, 1, 282-288.	1.1	6
76	Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1646-1652.	2.0	92
77	<sup>18</sup> F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation. <i>Journal of Nuclear Medicine</i> , 2011, 52, 386-392.	2.8	151
78	Exclusion of Malignancy in Thyroid Nodules with Indeterminate Fine-Needle Aspiration Cytology After Negative <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography: Interim Analysis. <i>World Journal of Surgery</i> , 2010, 34, 1247-1253.	0.8	52
79	Pelvic lymph node <sup>18</sup> F-fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. <i>Cancer</i> , 2010, 116, 1469-1475.	2.0	103
80	Lymph Node Staging by Positron Emission Tomography in Cervical Cancer: Relationship to Prognosis. <i>Journal of Clinical Oncology</i> , 2010, 28, 2108-2113.	0.8	262
81	Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. <i>Radiotherapy and Oncology</i> , 2010, 95, 288-291.	0.3	53
82	Prospective Study of [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Staging of Muscle-Invasive Bladder Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4314-4320.	0.8	219
83	Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor-Positive, Aromatase Inhibitor-Resistant Advanced Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 774.	3.8	252
84	Imaging Tumor Phenotype: 1 Plus 1 Is More Than 2. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1567-1569.	2.8	11
85	Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. <i>Gynecologic Oncology</i> , 2009, 112, 104-109.	0.6	84
86	Cervical cancer histology and tumor differentiation affect <sup>18</sup> F-fluorodeoxyglucose uptake. <i>Cancer</i> , 2009, 115, 3548-3554.	2.0	71
87	PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 509-517.	1.1	189
88	PET Radiotracers for Imaging the Proliferative Status of Solid Tumors. <i>PET Clinics</i> , 2009, 4, 1-15.	1.5	23
89	Surveillance FDG-PET Detection of Asymptomatic Recurrences in Patients. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 457-458.	0.2	0
90	Tumor Hypoxia Detected by Positron Emission Tomography with <sup>60</sup> Cu-ATSM as a Predictor of Response and Survival in Patients Undergoing Neoadjuvant Chemoradiotherapy for Rectal Carcinoma: A Pilot Study. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 1641-1648.	0.7	151

#	ARTICLE	IF	CITATIONS
91	Unique site- and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2008, 15, 483-487.	2.0	6
92	Combined [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for Detection of Recurrent, 131I-Negative Thyroid Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 286-292.	0.7	52
93	An Imaging Comparison of <sup>64</sup> Cu-ATSM and <sup>60</sup> Cu-ATSM in Cancer of the Uterine Cervix. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1177-1182.	2.8	178
94	Assessing Tumor Hypoxia in Cervical Cancer by PET with <sup>60</sup> Cu-Labeled Diacetyl-Bis( <i>N</i> - <sup>4</sup> -Methylthiosemicarbazone). <i>Journal of Nuclear Medicine</i> , 2008, 49, 201-205.	2.8	221
95	Prognostic Value of Preoperative Positron Emission Tomography in Resected Stage I Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 130-134.	0.5	104
96	Poor Predictive Value of FDG-PET/CT Performed after 2 Cycles of R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLCL). <i>Blood</i> , 2008, 112, 371-371.	0.6	13
97	Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2289.	3.8	260
98	The standardized uptake value for F <sup>18</sup> fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. <i>Cancer</i> , 2007, 110, 1738-1744.	2.0	271
99	Comparison of Molecular Markers of Hypoxia and Imaging with <sup>60</sup> Cu-ATSM in Cancer of the Uterine Cervix. <i>Molecular Imaging and Biology</i> , 2007, 9, 278-283.	1.3	88
100	A2-05: Prognostic value of positron emission tomography in resected stage I non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, S314.	0.5	0
101	F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. <i>Gynecologic Oncology</i> , 2006, 101, 147-151.	0.6	122
102	<sup>18</sup> F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1808-12.	2.8	183
103	FDG-PET evaluation of vaginal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 733-737.	0.4	103
104	Correlation of Severity of FDG-PET Hypometabolism and Interictal Regional Delta Slowing in Temporal Lobe Epilepsy. <i>Epilepsia</i> , 2005, 46, 573-576.	2.6	38
105	Clinical-pathologic conference in general thoracic surgery: Cardiac lymphoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 130, 870-874.	0.4	3
106	Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. <i>Cancer</i> , 2005, 104, 2484-2491.	2.0	168
107	Positron tomographic assessment of androgen receptors in prostatic carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 344-350.	3.3	216
108	FDG uptake in colonic villous adenomas. <i>Annals of Nuclear Medicine</i> , 2005, 19, 331-334.	1.2	25



#	ARTICLE	IF	CITATIONS
109	Positron Emission Tomography in Limited-Stage Small-Cell Lung Cancer: A Prospective Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 3248-3254.	0.8	250
110	Posttherapy [18F] Fluorodeoxyglucose Positron Emission Tomography in Carcinoma of the Cervix: Response and Outcome. <i>Journal of Clinical Oncology</i> , 2004, 22, 2167-2171.	0.8	228
111	Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. <i>Gynecologic Oncology</i> , 2004, 95, 546-551.	0.6	158
112	Neoplasms of the esophagus and stomach. <i>Seminars in Nuclear Medicine</i> , 2004, 34, 198-208.	2.5	52
113	Five-Year Survival After Resection of Hepatic Metastases From Colorectal Cancer in Patients Screened by Positron Emission Tomography With F-18 Fluorodeoxyglucose (FDG-PET). <i>Annals of Surgery</i> , 2004, 240, 438-450.	2.1	541
114	Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. <i>Gynecologic Oncology</i> , 2003, 90, 572-576.	0.6	94
115	Posttherapy surveillance monitoring of cervical cancer by FDG-PET. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 907-913.	0.4	102
116	Assessing tumor hypoxia in cervical cancer by positron emission tomography with <sup>60</sup> Cu-ATSM: Relationship to therapeutic response—a preliminary report. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 1233-1238.	0.4	324
117	Detection of Primary Hepatic Malignancy in Liver Transplant Candidates: Prospective Comparison of CT, MR Imaging, US, and PET. <i>Radiology</i> , 2003, 226, 533-542.	3.6	200
118	Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. <i>Journal of Nuclear Medicine</i> , 2003, 44, 192-7.	2.8	55
119	<sup>11</sup> C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. <i>Journal of Nuclear Medicine</i> , 2003, 44, 549-55.	2.8	209
120	Evaluation of <sup>111</sup> In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. <i>Journal of Nuclear Medicine</i> , 2003, 44, 700-7.	2.8	105
121	Usefulness of Intraoperative Sonography for Revealing Hepatic Metastases from Colorectal Cancer in Patients Selected for Surgery After Undergoing FDG PET. <i>American Journal of Roentgenology</i> , 2002, 178, 353-358.	1.0	60
122	Evaluation of breast and gynecologic cancers by positron emission tomography. <i>Seminars in Roentgenology</i> , 2002, 37, 151-168.	0.2	9
123	Prospective Evaluation of Positron Emission Tomography for the Detection of Groin Node Metastases from Vulvar Cancer. <i>Gynecologic Oncology</i> , 2002, 85, 179-184.	0.6	162
124	Lymph Node Staging by Positron Emission Tomography in Patients With Carcinoma of the Cervix. <i>Journal of Clinical Oncology</i> , 2001, 19, 3745-3749.	0.8	439
125	Metabolic Flare: Indicator of Hormone Responsiveness in Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 2797-2803.	0.8	377
126	Survival of Patients Evaluated by FDG-PET Before Hepatic Resection for Metastatic Colorectal Carcinoma: A Prospective Database Study. <i>Annals of Surgery</i> , 2001, 233, 293-299.	2.1	171



#	ARTICLE	IF	CITATIONS
127	Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. <i>Diseases of the Colon and Rectum</i> , 2000, 43, 759-767.	0.7	254
128	FDG PET Evaluation of Mucinous Neoplasms. <i>American Journal of Roentgenology</i> , 2000, 174, 1005-1008.	1.0	300
129	Characterizing Tumors Using Metabolic Imaging: PET Imaging of Cellular Proliferation and Steroid Receptors. <i>Neoplasia</i> , 2000, 2, 71-88.	2.3	81
130	Comparative breast tumor imaging and comparative in vitro metabolism of $^{16}\text{O}$ - $^{18}\text{F}$ Fluoroestradiol- $^{17}\text{O}$ and $^{16}\text{O}$ - $^{18}\text{F}$ fluoromoxestrol in isolated hepatocytes. <i>Nuclear Medicine and Biology</i> , 1999, 26, 123-130.	0.3	47
131	FDG-PET Evaluation of Carcinoma of the Cervix. <i>Molecular Imaging and Biology</i> , 1999, 2, 105-109.	0.3	63
132	PET in breast cancer. <i>Seminars in Nuclear Medicine</i> , 1998, 28, 290-302.	2.5	92
133	Utility of FDG-PET for Investigating Unexplained Plasma CEA Elevation in Patients With Colorectal Cancer. <i>Annals of Surgery</i> , 1998, 227, 319-323.	2.1	226
134	Improvement in Staging of Esophageal Cancer With the Addition of Positron Emission Tomography. <i>Annals of Thoracic Surgery</i> , 1997, 64, 770-777.	0.7	234
135	Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography. <i>Annals of Surgical Oncology</i> , 1997, 4, 613-620.	0.7	248
136	FDG-PET Evaluation of Indeterminate Pancreatic Masses. <i>Journal of Computer Assisted Tomography</i> , 1996, 20, 363-369.	0.5	78
137	False-Negative Radionuclide Cisternography in Massive Communicating Hydrocephalus: Value of the Vertex View and CT Correlation. <i>Clinical Nuclear Medicine</i> , 1989, 14, 819-822.	0.7	1
138	Scintigraphic Demonstration of a Large Communicating Posterior Fossa Cyst. <i>Clinical Nuclear Medicine</i> , 1989, 14, 627-628.	0.7	0
139	Diffuse Muscle Uptake of Technetium-99M MDP in a Patient with Lung Cancer. <i>Clinical Nuclear Medicine</i> , 1988, 13, 538-540.	0.7	2